Day: February 13, 2020

Home > Press > Arrowhead Reports Interim Clinical Data on Cardiometabolic Candidates ARO-APOC3 and ARO-ANG3Abstract:Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today reported promising interim clinical results from the ongoing Phase 1/2a studies of its two RNAi-based cardiometabolic candidates, ARO-APOC3 targeting apolipoprotein C-III (APOC3) being developed as a potential treatment for patients...